1
|
Escobar G, Tooley K, Oliveras JP, Huang L, Cheng H, Bookstaver ML, Edwards C, Froimchuk E, Xue C, Mangani D, Krishnan RK, Hazel N, Rutigliani C, Jewell CM, Biasco L, Anderson AC. Tumor immunogenicity dictates reliance on TCF1 in CD8 + T cells for response to immunotherapy. Cancer Cell 2023; 41:1662-1679.e7. [PMID: 37625402 PMCID: PMC10529353 DOI: 10.1016/j.ccell.2023.08.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 06/28/2023] [Accepted: 08/04/2023] [Indexed: 08/27/2023]
Abstract
Stem-like CD8+ T cells are regulated by T cell factor 1 (TCF1) and are considered requisite for immune checkpoint blockade (ICB) response. However, recent findings indicate that reliance on TCF1+CD8+ T cells for ICB efficacy may differ across tumor contexts. We find that TCF1 is essential for optimal priming of tumor antigen-specific CD8+ T cells and ICB response in poorly immunogenic tumors that accumulate TOX+ dysfunctional T cells, but is dispensable for T cell priming and therapy response in highly immunogenic tumors that efficiently expand transitory effectors. Importantly, improving T cell priming by vaccination or by enhancing antigen presentation on tumors rescues the defective responses of TCF1-deficient CD8+ T cells upon ICB in poorly immunogenic tumors. Our study highlights TCF1's role during the early stages of anti-tumor CD8+ T cell responses with important implications for guiding optimal therapeutic interventions in cancers with low TCF1+CD8+ T cells and low-neo-antigen expression.
Collapse
Affiliation(s)
- Giulia Escobar
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Katherine Tooley
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA; Division of Medical Sciences, Harvard Medical School, Boston, MA, USA
| | - Joan Pagès Oliveras
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Linglin Huang
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Hanning Cheng
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Michelle L Bookstaver
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Camilla Edwards
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA
| | - Eugene Froimchuk
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA
| | - Chang Xue
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Davide Mangani
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Rajesh K Krishnan
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Natanael Hazel
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Carola Rutigliani
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
| | - Christopher M Jewell
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA; US Department of Veterans Affairs, VA Maryland Health Care System, Baltimore, MD 21201, USA
| | - Luca Biasco
- Great Ormond Street Institute of Child Health, University College London, London, UK
| | - Ana C Anderson
- Evergrande Center for Immunologic Diseases, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
| |
Collapse
|
2
|
Bookstaver ML, Zeng Q, Oakes RS, Kapnick SM, Saxena V, Edwards C, Venkataraman N, Black SK, Zeng X, Froimchuk E, Gebhardt T, Bromberg JS, Jewell CM. Self-Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design. Adv Sci (Weinh) 2022; 10:e2202393. [PMID: 36373708 PMCID: PMC9811447 DOI: 10.1002/advs.202202393] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 10/14/2022] [Indexed: 05/28/2023]
Abstract
Recent clinical studies show activating multiple innate immune pathways drives robust responses in infection and cancer. Biomaterials offer useful features to deliver multiple cargos, but add translational complexity and intrinsic immune signatures that complicate rational design. Here a modular adjuvant platform is created using self-assembly to build nanostructured capsules comprised entirely of antigens and multiple classes of toll-like receptor agonists (TLRas). These assemblies sequester TLR to endolysosomes, allowing programmable control over the relative signaling levels transduced through these receptors. Strikingly, this combinatorial control of innate signaling can generate divergent antigen-specific responses against a particular antigen. These assemblies drive reorganization of lymph node stroma to a pro-immune microenvironment, expanding antigen-specific T cells. Excitingly, assemblies built from antigen and multiple TLRas enhance T cell function and antitumor efficacy compared to ad-mixed formulations or capsules with a single TLRa. Finally, capsules built from a clinically relevant human melanoma antigen and up to three TLRa classes enable simultaneous control of signal transduction across each pathway. This creates a facile adjuvant design platform to tailor signaling for vaccines and immunotherapies without using carrier components. The modular nature supports precision juxtaposition of antigen with agonists relevant for several innate receptor families, such as toll, STING, NOD, and RIG.
Collapse
Affiliation(s)
- Michelle L. Bookstaver
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Qin Zeng
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Robert S. Oakes
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
- United States Department of Veterans AffairsVA Maryland Health Care System10 North Greene StreetBaltimoreMD21201USA
| | - Senta M. Kapnick
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Vikas Saxena
- Department of SurgeryUniversity of Maryland School of MedicineBaltimoreMD21201USA
- Center for Vascular and Inflammatory DiseasesUniversity of Maryland School of MedicineBaltimoreMD21201USA
| | - Camilla Edwards
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Nishedhya Venkataraman
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Sheneil K. Black
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Xiangbin Zeng
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Eugene Froimchuk
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
| | - Thomas Gebhardt
- Department of Microbiology and ImmunologyThe University of Melbourne at the Peter Doherty Institute for Infection and ImmunityMelbourneVictoriaAustralia
| | - Jonathan S. Bromberg
- Department of SurgeryUniversity of Maryland School of MedicineBaltimoreMD21201USA
- Center for Vascular and Inflammatory DiseasesUniversity of Maryland School of MedicineBaltimoreMD21201USA
- Department of Microbiology and ImmunologyUniversity of Maryland School of Medicine685 West Baltimore StreetBaltimoreMD21201USA
| | - Christopher M. Jewell
- Fischell Department of BioengineeringUniversity of Maryland8278 Paint Branch DriveCollege ParkMD20742USA
- United States Department of Veterans AffairsVA Maryland Health Care System10 North Greene StreetBaltimoreMD21201USA
- Department of Microbiology and ImmunologyUniversity of Maryland School of Medicine685 West Baltimore StreetBaltimoreMD21201USA
- Robert E. Fischell Institute for Biomedical Devices8278 Paint Branch DriveCollege ParkMD20742USA
- Marlene and Stewart Greenebaum Cancer Center22 South Greene StreetBaltimoreMD21201USA
| |
Collapse
|
3
|
Cano-Mejia J, Bookstaver ML, Sweeney EE, Jewell CM, Fernandes R. Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma. Biomater Sci 2019; 7:1875-1887. [PMID: 30789175 DOI: 10.1039/c8bm01553h] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
We describe the synthesis of CpG oligodeoxynucleotide-coated Prussian blue nanoparticles (CpG-PBNPs) that function as a nanoimmunotherapy for neuroblastoma, a common childhood cancer. These CpG-PBNPs increase the antigenicity and adjuvanticity of the treated tumors, ultimately driving robust antitumor immunity through a multi-pronged mechanism. CpG-PBNPs are synthesized using a facile layer-by-layer coating scheme resulting in nanoparticles that exhibit monodisperse size distributions and multiday stability without cytotoxicity. The strong intrinsic absorption of PBNPs in the CpG-PBNPs enables ablative photothermal therapy (CpG-PBNP-PTT) that triggers tumor cell death, as well as the release of tumor antigens to increase antigenicity. Simultaneously, the CpG coating functions as an exogenous molecular adjuvant that complements the endogenous adjuvants released by the CpG-PBNP-PTT (e.g. ATP, calreticulin, and HMGB1). In cell culture, coating NPs with CpG increases immunogenicity while maintaining the photothermal activity of PBNPs. When administered in a syngeneic, Neuro2a-based, murine model of neuroblastoma, CpG-PBNP-PTT results in complete tumor regression in a significantly higher proportion (70% at 60 days) of treated animals relative to controls. Furthermore, the long-term surviving, CpG-PBNP-PTT-treated animals reject Neuro2a rechallenge, suggesting that this therapy generates immunological memory. Our findings point to the importance of simultaneous cytotoxicity, antigenicity, and adjuvanticity to generate robust and persistent antitumor immune responses against neuroblastoma.
Collapse
Affiliation(s)
- Juliana Cano-Mejia
- The George Washington Cancer Center, The George Washington University, Washington, DC 20052, USA
| | | | | | | | | |
Collapse
|
4
|
Bookstaver ML, Hess KL, Jewell CM. Self-Assembly of Immune Signals Improves Codelivery to Antigen Presenting Cells and Accelerates Signal Internalization, Processing Kinetics, and Immune Activation. Small 2018; 14:e1802202. [PMID: 30146797 PMCID: PMC6252008 DOI: 10.1002/smll.201802202] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 07/15/2018] [Indexed: 04/14/2023]
Abstract
Vaccines and immunotherapies that elicit specific types of immune responses offer transformative potential to tackle disease. The mechanisms governing the processing of immune signals-events that determine the type of response generated-are incredibly complex. Understanding these processes would inform more rational vaccine design by linking carrier properties, processing mechanisms, and relevant timescales to specific impacts on immune response. This goal is pursued using nanostructured materials-termed immune polyelectrolyte multilayers-built entirely from antigens and stimulatory toll-like receptors agonists (TLRas). This simplicity allows isolation and quantification of the rates and mechanisms of intracellular signal processing, and the link to activation of distinct immune pathways. Each vaccine component is internalized in a colocalized manner through energy-dependent caveolae-mediated endocytosis. This process results in trafficking through endosome/lysosome pathways and stimulation of TLRs expressed on endosomes/lysosomes. The maximum rates for these events occur within 4 h, but are detectable in minutes, ultimately driving downstream proimmune functions. Interestingly, these uptake, processing, and activation kinetics are significantly faster for TLRas in particulate form compared with free TLRa. Our findings provide insight into specific mechanisms by which particulate vaccines enhance initiation of immune response, and highlight quantitative strategies to assess other carrier technologies.
Collapse
Affiliation(s)
- Michelle L. Bookstaver
- Fischell Department of Bioengineering, University of Maryland, 8278 Paint Branch Drive, College Park, MD 20742
| | - Krystina L. Hess
- Fischell Department of Bioengineering, University of Maryland, 8278 Paint Branch Drive, College Park, MD 20742
| | - Christopher M. Jewell
- Fischell Department of Bioengineering, University of Maryland, 8278 Paint Branch Drive, College Park, MD 20742
- United States Department of Veterans Affairs, VA Maryland Health Care System, 10 North Greene Street, Baltimore, Maryland 21201
- Robert E. Fischell Institute for Biomedical Devices, 8278 Paint Branch Drive, College Park, MD 20742, USA
- Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201
- Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201
| |
Collapse
|
5
|
Rhoads MK, Hauk P, Gupta V, Bookstaver ML, Stephens K, Payne GF, Bentley WE. Modification and Assembly of a Versatile Lactonase for Bacterial Quorum Quenching. Molecules 2018; 23:E341. [PMID: 29415497 PMCID: PMC6016966 DOI: 10.3390/molecules23020341] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Revised: 01/23/2018] [Accepted: 01/23/2018] [Indexed: 01/05/2023] Open
Abstract
This work sets out to provide a self-assembled biopolymer capsule activated with a multi-functional enzyme for localized delivery. This enzyme, SsoPox, which is a lactonase and phosphotriesterase, provides a means of interrupting bacterial communication pathways that have been shown to mediate pathogenicity. Here we demonstrate the capability to express, purify and attach SsoPox to the natural biopolymer chitosan, preserving its activity to "neutralize" long-chain autoinducer-1 (AI-1) communication molecules. Attachment is shown via non-specific binding and by engineering tyrosine and glutamine affinity 'tags' at the C-terminus for covalent linkage. Subsequent degradation of AI-1, in this case N-(3-oxododecanoyl)-l-homoserine lactone (OdDHL), serves to "quench" bacterial quorum sensing (QS), silencing intraspecies communication. By attaching enzymes to pH-responsive chitosan that, in turn, can be assembled into various forms, we demonstrate device-based flexibility for enzyme delivery. Specifically, we have assembled quorum-quenching capsules consisting of an alginate inner core and an enzyme "decorated" chitosan shell that are shown to preclude bacterial QS crosstalk, minimizing QS mediated behaviors.
Collapse
Affiliation(s)
- Melissa K Rhoads
- Institute for Bioscience and Biotechnology Research (IBBR), University of Maryland, College Park, MD 20742, USA.
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| | - Pricila Hauk
- Institute for Bioscience and Biotechnology Research (IBBR), University of Maryland, College Park, MD 20742, USA.
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| | - Valerie Gupta
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| | - Michelle L Bookstaver
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| | - Kristina Stephens
- Institute for Bioscience and Biotechnology Research (IBBR), University of Maryland, College Park, MD 20742, USA.
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| | - Gregory F Payne
- Institute for Bioscience and Biotechnology Research (IBBR), University of Maryland, College Park, MD 20742, USA.
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| | - William E Bentley
- Institute for Bioscience and Biotechnology Research (IBBR), University of Maryland, College Park, MD 20742, USA.
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA.
| |
Collapse
|
6
|
Bookstaver ML, Tsai SJ, Bromberg JS, Jewell CM. Improving Vaccine and Immunotherapy Design Using Biomaterials. Trends Immunol 2017; 39:135-150. [PMID: 29249461 DOI: 10.1016/j.it.2017.10.002] [Citation(s) in RCA: 120] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 09/29/2017] [Accepted: 10/03/2017] [Indexed: 12/13/2022]
Abstract
Polymers, lipids, scaffolds, microneedles, and other biomaterials are rapidly emerging as technologies to improve the efficacy of vaccines against infectious disease and immunotherapies for cancer, autoimmunity, and transplantation. New studies are also providing insight into the interactions between these materials and the immune system. This insight can be exploited for more efficient design of vaccines and immunotherapies. Here, we describe recent advances made possible through the unique features of biomaterials, as well as the important questions for further study.
Collapse
Affiliation(s)
- Michelle L Bookstaver
- Fischell Department of Bioengineering, University of Maryland, 8228 Paint Branch Drive, College Park, MD 20742, USA
| | - Shannon J Tsai
- Fischell Department of Bioengineering, University of Maryland, 8228 Paint Branch Drive, College Park, MD 20742, USA
| | - Jonathan S Bromberg
- Department of Surgery, University of Maryland School of Medicine, 29 South Greene Street, Baltimore, MD 21201, USA; Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, 800 West Baltimore Street, Baltimore, MD 21201, USA; Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA.
| | - Christopher M Jewell
- Fischell Department of Bioengineering, University of Maryland, 8228 Paint Branch Drive, College Park, MD 20742, USA; Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA; Marlene and Stewart Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA; United States Department of Veteran Affairs, 10 North Greene Street, Baltimore, MD 21201, USA.
| |
Collapse
|
7
|
Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM. Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Mol Pharm 2017; 14:1047-1056. [PMID: 28248115 DOI: 10.1021/acs.molpharmaceut.6b00919] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The receptor tyrosine kinase HER3 has emerged as a therapeutic target in ovarian, prostate, breast, lung, and other cancers due to its ability to potently activate the PI3K/Akt pathway, especially via dimerization with HER2, as well as for its role in mediating drug resistance. Enhanced efficacy of HER3-targeted therapeutics would therefore benefit a wide range of patients. This study evaluated the potential of multivalent presentation, through protein engineering, to enhance the effectiveness of HER3-targeted affibodies as alternatives to monoclonal antibody therapeutics. Assessment of multivalent affibodies on a variety of cancer cell lines revealed their broad ability to improve inhibition of Neuregulin (NRG)-induced HER3 and Akt phosphorylation compared to monovalent analogues. Engineered multivalency also promoted enhanced cancer cell growth inhibition by affibodies as single agents and as part of combination therapy approaches. Mechanistic investigations revealed that engineered multivalency enhanced affibody-mediated HER3 downregulation in multiple cancer cell types. Overall, these results highlight the promise of engineered multivalency as a general strategy for enhanced efficacy of HER3-targeted therapeutics against a variety of cancers.
Collapse
Affiliation(s)
- John S Schardt
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Jinan M Oubaid
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Sonya C Williams
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - James L Howard
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Chloe M Aloimonos
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Michelle L Bookstaver
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Tek N Lamichhane
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Sonja Sokic
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States
| | - Mariya S Liyasova
- Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892, United States
| | - Maura O'Neill
- Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research , Frederick, Maryland 21702, United States
| | - Thorkell Andresson
- Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research , Frederick, Maryland 21702, United States
| | - Arif Hussain
- Baltimore VA Medical Center , Baltimore, Maryland 21201, United States.,Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine , Baltimore, Maryland 21201, United States
| | - Stanley Lipkowitz
- Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892, United States
| | - Steven M Jay
- Fischell Department of Bioengineering, University of Maryland , College Park, Maryland 20742, United States.,Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine , Baltimore, Maryland 21201, United States.,Program in Molecular and Cellular Biology, University of Maryland , College Park, Maryland 20742, United States
| |
Collapse
|
8
|
Zhang P, Bookstaver ML, Jewell CM. Engineering Cell Surfaces with Polyelectrolyte Materials for Translational Applications. Polymers (Basel) 2017; 9:E40. [PMID: 30970718 PMCID: PMC6431965 DOI: 10.3390/polym9020040] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 01/18/2017] [Accepted: 01/19/2017] [Indexed: 11/16/2022] Open
Abstract
Engineering cell surfaces with natural or synthetic materials is a unique and powerful strategy for biomedical applications. Cells exhibit more sophisticated migration, control, and functional capabilities compared to nanoparticles, scaffolds, viruses, and other engineered materials or agents commonly used in the biomedical field. Over the past decade, modification of cell surfaces with natural or synthetic materials has been studied to exploit this complexity for both fundamental and translational goals. In this review we present the existing biomedical technologies for engineering cell surfaces with one important class of materials, polyelectrolytes. We begin by introducing the challenges facing the cell surface engineering field. We then discuss the features of polyelectrolytes and how these properties can be harnessed to solve challenges in cell therapy, tissue engineering, cell-based drug delivery, sensing and tracking, and immune modulation. Throughout the review, we highlight opportunities to drive the field forward by bridging new knowledge of polyelectrolytes with existing translational challenges.
Collapse
Affiliation(s)
- Peipei Zhang
- Fischell Department of Bioengineering, University of Maryland, College Park, MA 20742, USA.
| | - Michelle L Bookstaver
- Fischell Department of Bioengineering, University of Maryland, College Park, MA 20742, USA.
| | - Christopher M Jewell
- Fischell Department of Bioengineering, University of Maryland, College Park, MA 20742, USA.
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MA 21201, USA.
- Marlene and Stewart Greenebaum Cancer Center, Baltimore, MA 21201, USA.
- United States Department of Veterans Affairs, Baltimore, MA 21201, USA.
| |
Collapse
|